Plasmapheresis Market

Plasmapheresis Market Outlook (2025 to 2035)

The global Plasmapheresis market is expected to reach USD 3,497 Million by 2035, up from USD 1,528 Million in 2024. During the forecast period (2025 to 2035), the industry is projected to expand at a CAGR of 7.8%. Over the span of next ten years, the industry is poised to grow 2.1X with absolute dollar opportunity of USD 1,846.8 Million.

Plasmapheresis is a procedure that removes useful components from the blood plasma by filtering. It is relevant in the treatment of autoimmune disorders such as Guillain-Barré syndrome, myasthenia gravis and lupus. It works by eliminating its causes, which effectively reduces both symptoms and progression of disease, and is used when more medications that are conventional fail or as an emergency measure.

Metric	Value
Industry Size (2025E)	USD 1,650 Million
Industry Value (2035F)	USD 3,497 Million
CAGR (2025 to 2035)	7.8%

The market for plasmapheresis is essential for modern healthcare as it allows for the separation and collection of plasma for both therapeutic and donation reasons. It enables treatment for a range of autoimmune, neurological and hematological disorders by filtering out harmful antibodies or toxins from a patient’s blood.

Plasmapheresis is also critical for the supply of plasma used to create life-saving biologics, such as immunoglobulins and clotting factors. Thus, rising complement of plasma-derived therapies, improvement in medical technologies, and expanding healthcare infrastructure are contributing to the fitting growth of plasmapheresis procedures in hospital as well as outpatient settings in any of the worldwide markets.

The plasmapheresis market is anticipated to register robust and sustained growth throughout the upcoming years, owing to increasing demand for plasma-derived therapeutics and a growing number of clinical applications. Further developments in automation, portability, and safety of apheresis systems are leading to the wider adoption of plasmapheresis by healthcare facilities for enhanced treatment and collection capabilities.

The attention of the global clinical community on rare disease therapies and the increasing investment in blood and plasma infrastructure will drive the expansion of this market. As new economies develop a more robust healthcare infrastructure while adhering to global standards, the plasmapheresis market stands to contribute significantly to personalized and regenerative medicine.

What factors are driving growth in the global plasmapheresis market across healthcare and therapeutic applications?

Over the last few years’ plasmapheresis is gaining recognition as a significant process in the areas of therapeutic treatment and blood components collection. Growth of this market is directly related to higher occurrences of autoimmune diseases, neurological disorders, and hematologic disorders, which benefits from plasma exchange procedures.

The emergence of precision medicine and biologics further increases the importance of plasma as a core raw material. The ever-expanding infrastructure for plasma donations worldwide, particularly in developing regions, and a rising dependence on immunoglobulins and albumin-based therapies are supplementing both demand and technological advancements.

On the technology side of things, automation and integration with AI-powered monitoring systems are increasing workflow efficiency and improving safety. This is raising the adoption of plasmapheresis procedures in hospitals, standalone clinics and mobile blood donation setups. Encouragement from the regulatory environment, particularly in the United States and parts of Europe, is another key driver for both plasma donors and collection institutions to take the plunge into high-quality collection infrastructure.

Which product type is the fastest-growing segment in the plasmapheresis market?

Within the plasmapheresis market, the Disposables segment is outgrowing the Instruments category in terms of volume and value growth, making it the fastest-growing segment in this market. The main reason for this significant growth is the indispensable use of disposables in every plasmapheresis process.

If you live near a hospital that uses blood donation equipment, it is important to remember that items such as tubing sets, filters, collection bags, and needles are single-use by design, so there is a consumption-focused, recurring need from hospitals, blood banks, and mobile donation units for these devices after every session.

The rising focus on infection prevention and patient safety has further solidified the desire for single-use components, particularly following increased public consciousness regarding transmissible diseases worldwide. In an increasingly sterile world, disposables answer the call of maintaining rigorous safety standards, increasing reliability and preventing cross-contamination. In addition, constant innovations in material science has resulted in the futuristic biocompatible, easy to wear, and user-friendly designs, making them even more popular among practitioners as well as patients.

Unlike capital-intensive instruments, which have prolonged procurement and upgrade cycles, disposables enable ongoing consumption and a faster replenishment cycle. Being an essential aspect of therapeutic and donor plasmapheresis and having clinical safety guidelines, disposables emerge as the strongest and most dynamic growth driver within the product segmentation.

What regional trends are driving the growth of the plasmapheresis market across North America and Asia?

North America remains at the forefront of the plasmapheresis market worldwide, owing to the established healthcare infrastructure in the region along with favorable reimbursement scenario and high awareness levels. The US is the number one market, with heavy investment in therapeutic plasma product development and a big pool of plasma donors. Agencies like the FDA oversee a rigorous framework balancing safety and efficacy with innovation.

Countries in East Asia, led by China, Japan, and South Korea are quickly becoming an important growth engine, as they start to extend their plasma collection networks and drive greater domestic self-sufficiency in plasma-derived therapies. A vigorous regional momentum is being supported by government-led public health campaigns and an increasing investment in biotechnology.

Another major market is Western Europe, where public healthcare systems are already established, which leads to the increase in demand for immunoglobulins and albumin. These countries have strong collection frameworks in place and are front-runners in terms of regional production capacity. Yet ethical problems related to paid plasma donation and strong regulatory controls sometimes get in the way.

What are the key trends in the global plasmapheresis market in recent years?

Rapid adoption of disposable kits and automated systems resulting in safe procedures with reduced time gaining traction across various service providers are some of the factors being referred to. In addition, the audit of digital monitoring and real-time data tracking into apheresis machines is being increasingly adopted to improve efficiency and patient outcomes.

In developed countries, this trend is growing due to better accessibility and reduced costs of outpatient plasmapheresis procedures. Joint public and private partnerships are driving development of plasma collection networks. This increased focus on donor safety and comfort is resulting in innovations in device design and user interfaces, driving increased adoption from patients and clinicians alike.

Why does the high cost of plasmapheresis procedures hinder access in developing healthcare systems?

While with a positive forecast, the plasmapheresis market also faces key restraints, which primarily include high cost of equipment and a lack of access in low-income regions. Ethical issues and regulatory prohibitions regarding paid plasma donations also may constrain the expansion of donor pools.

The operational intricacies of this procedure, along with the dependence on trained personnel and requisite infrastructure, make it challenging for smaller clinics and developing markets. The risk of side effects such as dizziness, bleeding, or allergic reactions could deter patients and donors from different sessions. Uneven global regulations and reimbursement policies create additional challenges to achieving widespread market growth.

Shifts in the Plasmapheresis Market from 2020 to 2024 and Future Trends 2025 to 2035

Between 2020 and 2024, the plasmapheresis market displayed a resilient and upward trend, largely contributed by rising awareness and prevalence of autoimmune and neurological disorders including Guillain-Barré syndrome, myasthenia gravis, and multiple sclerosis.

This period saw the FDA, EMA and the like working to grant emergency use authorizations and accelerated approvals for plasmapheresis applications in immunomodulation and rare disease treatment. Improvements in apheresis machines-especially in automation, filtration precision, and biocompatibility-boosted procedural safety and efficiency.

On the other hand, biopharmaceutical companies and clinical research organizations hastened the implementation of plasma collection programs, while centralized plasma fractionation and supply networks were the foundation of the global market.

The plasmapheresis market will see substantial structural changes with innovations in extracorporeal therapy platforms, AI-enabled donor screening, and integrated electronic health data that will enhance patient matching and collection optimization from 2025 to 2035.

The global transition to personalized and precision medicine will necessitate more individualized plasmapheresis protocols, particularly for handling orphaned immunological and hematological diseases. Regulatory systems will shift toward harmonized frameworks with sustainability mandates, particularly relating to donor ethics, single-use device waste, and biologic supply chains.

Regional manufacturing and decentralized collection centers will spring up, catering to increased demand without the need for international logistics. The therapeutic plasmapheresis sector is predicted to witness new use cases in oncology, restorative medicine, and cell-based treatments over the forecasted timeframe, a diversification from existing autoimmune applications.

Comparative Market Analysis

Market Shift	2020 to 2024
Regulatory Landscape	Emergency use approvals and fast-tracked clinical validations, particularly during the pandemic. Emphasis on safety in plasma extraction and donor protocols.
Technological Advancements	Advancements in automated plasmapheresis machines, filtration systems, and donor monitoring tools. Increased throughput in plasma collection centers.
Industry-Specific Demand	High demand from hospitals, blood banks, and biopharma companies focused on immunoglobulin and albumin production.
Sustainability & Circular Economy	Initial steps toward reducing single-use plastic in apheresis kits. Limited environmental oversight in plasma logistics.
Production & Supply Chain	Reliance on centralized plasma collection and fractionation facilities. Globalized logistics networks vulnerable to disruptions.
Market Growth Drivers	Rise in autoimmune disorders, pandemic-driven demand for plasma, technological advances in extraction devices.

Market Shift	2025 to 2035
Regulatory Landscape	Broader regulatory convergence around biologic safety, traceability, and donor protection. New mandates targeting environmental compliance and AI-driven diagnostic workflows.
Technological Advancements	Rise of AI-enabled apheresis systems, smart donor-matching algorithms, and integration with real-time patient analytics. Broader adoption of wearable diagnostics to guide therapy timing.
Industry-Specific Demand	Expansion into regenerative medicine, oncology adjunct treatments, and cell therapy manufacturing. Greater involvement from personalized medicine and AI-healthcare startups.
Sustainability & Circular Economy	Implementation of green manufacturing principles, biodegradable device components, and localized, circular collection networks to reduce environmental footprint.
Production & Supply Chain	Shift to decentralized, AI-optimized donor collection hubs. Enhanced local manufacturing to mitigate risk and enable just-in-time biologic production.
Market Growth Drivers	Expansion of therapeutic indications, AI-guided collection and treatment optimization, and sustainable operational practices in biologics.

Future Outlook (2025 to 2035)

Over the next few years plasmapheresis will metamorphosis from a largely hospital-based (and predominantly autoimmune) therapy toolbox into a multi-functional platform seamlessly adapted into precision treatment pathways. AI tools will enhance donor suitability determinations, increase the volume of plasma collected and automate when machines are calibrated-making them safer and more efficient.

Plasmapheresis will further proliferate into related disciplines, including, inter alias, oncology for manipulation of cytokines, and regenerative medicine (cell preparation and cleansing), allowing it to the achieve significantly greater clinical flexibility.

This will force regulators to find a balance between fostering innovation and ensuring patient safety through real-time monitoring and traceability of each plasma unit, from donor to therapeutic application. Simultaneously, environmental pressures will accelerate a shift towards reusability, material innovation, and regional supply loops.

Continued momentum in the market will be sustained through increased health care investments, expanded use in emerging clinical fields and a global push toward more personalized, biologic-based therapies. Medically precise digital knowledge systems that contribute to environmental responsibility are the future of plasmapheresis.

Country-Wise Outlook

Country	CAGR (2025 to 2035)
United States	7.5%
Germany	7.0%
China	7.8%

United States

The United States plasmapheresis market is projected to flourish, owing to increasing demand for plasma-derived therapies and a rising number of autoimmune and neurological disorders such as myasthenia gravis and Guillain-Barre syndrome. Highly developed healthcare infrastructure with widespread donor and therapeutic plasmapheresis procedures owing to the well-established blood donation networks.

Improved reimbursement policies and FDA approvals for new apheresis devices have increased patient access and stimulated innovation. Dominance of clinical trial pipeline in the U.S. and continued investments by large biopharmaceutical companies on the plasma fractionation facility contribute to the advantageous situation of the U.S. Market growth is also supported by a growing geriatric population, increasing cases of rare diseases, as well as expanding indications for plasmapheresis.

Germany

Top-end plasma fractionation and transfusion medicines are particularly pronounced in the European plasmapheresis market, emphasized here in Germany. The United States relies heavily on voluntary blood and plasma donation, which provides a steady flow for fractionation and therapeutic use.

This has led to an increased procedural safety in Germany due to the ever-growing number of automated plasmapheresis systems that are being introduced at both hospitals and apheresis centers. The rising prevalence of chronic autoimmune disorders and neurological disorders, in addition to favorable health insurance reimbursement for the plasma-derived therapies, boost the growth of this market.

Lastly, Germany's constitutional obligation to follow EU regulations and quality standards and its commitment to participate in European efforts for rare diseases (also called "orphan" diseases), put Germany in front of the pack in the areas of clinical, research, and application of therapeutic plasmapheresis.

China

The plasmapheresis market in China is expanding quickly owing to the modernization of healthcare infrastructure, greater awareness of rare and immune-mediated diseases, and a growing number of plasma donation centers. China is pushing volume, but cutting back on outsourced plasma products, thereby promoting the local production and development.

Traditional medicine has its place, but urban hospitals are adopting automated apheresis systems and preparing GMP, international standards. The country’s sizable population base and aging demographic also bode well for the long-term market potential, particularly when it comes to treating chronic neurological and hematological conditions.

Category-Wise Market Outlook

Plasmapheresis Market by Product

The product category is seeing disposables jump as the fastest-growing segment. This increase can primarily be attributed to repeated usage per plasmapheresis procedure, as disposables are single-use devices that maintain sterility and patient safety.

Increasing number of therapeutic procedures and plasma collection activities around the world are fueling constant demand for consumables such as tubing, plasma filters, and collection bags. Furthermore, growing infection control measures being implemented in hospitals and blood banks is also driving the demand for superior quality disposables.

Plasmapheresis Market by Technology

Among the plasmapheresis technologies, membrane filtration is the fastest growing segment. This increase is mainly due to its superiority over centrifugation, including higher precision in plasma separation, negligible damage to cells, and reduced risk of contamination.

Its effectiveness without spinning mechanisms and processing through vast membrane pore sizes favor its use in advanced therapeutic applications. Moreover, the use of membrane-based systems has grown as components of automated plasmapheresis machines, facilitating higher efficiency and broader adoption in biopharmaceutical and clinical settings

Plasmapheresis Market by End-User

Biopharmaceutical Companies is the fast-ageing end-user segment in the market. This trend is being fueled by the increasing demand for blood plasma-derived therapies like immunoglobulins, clotting factors, and albumin. These companies are expanding plasma collection operations as the therapeutic demand expands to treat rare diseases and immunodeficiencies.

Moreover, the growing number of collaborations between plasma collection centers and biopharma companies, and the approvals for new plasma therapies by regulatory authorities, is further propelling the growth of this segment.

Plasmapheresis Market by Application

Application segment focus on Source Plasma Collection, which is currently the main growth segment in the business. The growth of this segment is driven by the increased demand for plasma-based medicines worldwide. With chronic diseases and autoimmune disorders on the rise, biopharmas are stepping up their scramble to access large amounts of feedstock plasma for fractionation.

Moreover, the growing demand for voluntary plasma donation programs and the expanded infrastructural setup for plasma collection centers (especially in United States and portion of Europe) are some other factors that are fostering the growth of this application area.

Competitive Analysis

Technological advancements are also expected to pave the way for increasing adoption of plasmapheresis procedures and contribute to the overall growth of the plasmapheresis market. Surging requirement for Source Plasma used for fractionation, and rising incidence of therapeutic plasmapheresis procedures, are expected to favors global market growth, particularly in North America and Asia-Pacific Region.

Innovative technologies like automated plasmapheresis devices, closed-loop collection systems, and user-friendly interfaces are improving donor safety, efficiency, and comfort. It also additional regulatory support and higher investments in plasma fractionation facilities are driving this market's infrastructure.

The national market is moderately consolidated, with such players in relevant sectors as Haemonetics Corporation, Terumo BCT, and Fresenius Kabi rank among the most prominent in both technology and service categories. But regional and emerging players are increasingly penetrating through effective solutions and partnerships with blood collection centers & hospitals.

Another growth domain for this market region is Asia-Pacific and Latin America because of better access to healthcare, favorable government initiatives directing voluntary donation of plasma, and more improved diagnostic and treatment infrastructure.

Some of the major players in the Plasmapheresis Market are Haemonetics Corporation, Asahi Kasei Kuraray Medical Co. Ltd., Terumo Corporation, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Kawasumi Laboratories Inc., Kaneka Corporation, Other Key Players.

As they are going to expend a part of their income (return from investments) on R&D, they are always going to look forward to purchasing solutions of the problems which will attract new customers towards them and give them an upper edge than the other competitors. These companies bring specialized services to a particular niche market, and performing this allows them to be distinct from the second kind of companies because they can learn and innovate while being in the business.

Company Name	Estimated Market Share (%), 2024
Top 5 players	~70-75%
Tier II players	~10-15%
Others	~05-10%

Key Company Offerings and Activities

Company Name	Key Offerings/Activities
Haemonetics Corporation	Offers automated plasmapheresis systems (e.g., NexSys PCS). Focuses on donor safety, collection efficiency, and global plasma center partnerships.
Asahi Kasei Kuraray Medical Co. Ltd.	Specializes in membrane-based plasmapheresis devices (e.g., Plasmaflo). Provides selective plasma component separation solutions for therapeutic use.
Terumo Corporation	Delivers advanced blood component and apheresis systems. Emphasizes closed-loop systems, donor comfort, and real-time monitoring features.
B. Braun Melsungen AG	Develops therapeutic apheresis and infusion therapy devices. Focuses on safety-oriented innovations and supports hospital-based procedures.
Baxter International Inc.	Supplies blood purification and plasma exchange systems. Invests in integrated care models and technologies for autoimmune and neurological disorders.
Fresenius SE & Co. KGaA	Offers therapeutic apheresis devices and blood separation systems. Strong presence in hospitals with a focus on chronic disease management.
Kawasumi Laboratories Inc.	Produces cost-effective manual and semi-automated apheresis devices. Prioritizes accessibility and usability in resource-limited settings.
Kaneka Corporation	Provides selective plasma exchange systems and bioprocessing membranes. Focuses on precision medicine and clinical applications in nephrology and neurology.
Other Key Players	Offer portable and versatile plasmapheresis solutions tailored for regional needs. Emphasize affordability, technical support, and localized distribution.

Key Company Insights

Haemonetics Corporation

Haemonetics Corporation is a leading innovator in plasmapheresis technologies and its NexSys PCS is among the most well-known automated systems. However, donor safety, streamlined collection volumes and shorter procedure times drive development for many high-throughput plasma centers.

While it has made considerable progress in software integration, which allows for data monitoring and automated workflows for collection centers in real time. A market leader and committed to smart, scalable solutions through strong collaborations with global plasma donation networks.

Asahi Kasei Kuraray Medical Co.

With its Plasmaflo line of products, Asahi Kasei Kuraray Medical specializes in membrane-based plasmapheresis systems used in clinical settings. It provides selective plasma exchange for treating complex neurological and autoimmune disorders.

Asahi Kasei is confident in the future development of global preclinical and clinical research, while continuing to develop data with one goal in mind, therapeutic safety. Its technology is prized for allowing targeted plasma filtration with a low loss of whole blood and reduced patient discomfort.

Terumo Corporation

Terumo Corporation, a leading provider of blood and plasma separation systems for both donation and therapeutic use. Its devices are characterized by ergonomic design, automation, and sophisticated donor safety features. Terumo is making waves in the apheresis space with closed-loop systems and intuitive interfaces that enhance clinician workflow and patient experience. To address developed and emerging healthcare markets, the company is spreading its global reach.

B. Braun Melsungen AG

B. Braun Melsungen AG offers therapeutic apheresis solutions as part of its extensive infusion therapy and clinical care products portfolio. Its innovative devices also help make hospitals safer, while standardizing equipment across facilities.

StanBio is a 40-year-old company with expertise in providing high-quality products for protein purification in blood, plasma, serum, and tissue samples; with a focus of innovation in the fields of fluid management and extracorporeal therapy, B. Braun and its plasmapheresis solutions are ideally suited for utilization in multidisciplinary treatment centers-a critical need for complex cases.

Other Key Market Players

This segment includes regional companies, contract manufacturers, and specialized device providers, extending the reach of plasmapheresis technologies to new and existing markets. Several companies including Baxter International, B. Braun Melsungen AG, etc. provide flexible systems and customized kits for use in hospitals, outpatient clinics and homecare settings for therapeutic purposes.

They focus on price, user-friendliness and interoperability with existing healthcare infrastructure. They are, of course, infinitely more important in developing regions-Asia-Pacific, Latin America and Africa, where healthcare access to both patients and their doctors is limited-but where there is growing access to the need for plasma therapies and the necessity for efficient and adaptable plasmapheresis solutions.

Recent Development

• In January 2025, Fresenius Kabi received FDA 510(k) clearance for its Adaptive Nomogram, integrated into the Aurora Xi Plasmapheresis System. This cutting-edge algorithm customizes plasma collection per donor, boosting yield by 11.5% without compromising safety. It significantly enhances collection efficiency, supporting rising demand for plasma-derived therapies.
• ​In August 2023, Terumo Blood and Cell Technologies received FDA clearance for its Reveos® Automated Whole Blood Processing System, the first device in the U.S. capable of processing whole blood into platelets and other components in a single centrifugation cycle. This innovation aims to enhance blood center efficiency and bolster platelet availability. ​

Fact.MR has provided detailed information about the price points of key manufacturers of Plasmapheresis Market positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Segmentation of Plasmapheresis Market Research

• By Product :

  • Instruments
  • Disposables

• By Technology :

  • Membrane Filtration
  • Centrifugation

• By End-User :

  • Biopharmaceutical
  • Companies, Hospitals & Clinics
  • Other End Users

• By Application :

  • Therapeutic Plasmapheresis
  • Source Plasma Collection

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa